Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Last updated: 3 September 2026

Clear filter
682 clinical trials found
Clinical trials

BG C477 101

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors (NCT06596473)

Currently recruiting

BG-C0902-101

A Phase 1a/b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C0902, an Antibody-Drug Conjugate Targeting EGFR MET, Alone and in Combination with Other Therapeutic Agents in Patients with Advanced Solid Tumors (NCT07181681)

This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study aims to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C0902 in participants with advanced solid tumors. The study will be conducted in 2 phases: Phase 1a (dose escalation and safety expansion) and Phase 1b (dose expansion).
Currently recruiting

BGB-11417-101

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies (BGB-11417-101) (NCT04277637)

No longer recruiting

BGB-11417-103

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (NCT04771130)

Currently recruiting

BGB-11417-105

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) (NCT04973605)

Currently recruiting

BGB-11417-108

A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule[s] in Adult Patients With Hematological Malignancies. (NCT06697184)

Currently recruiting

BGB-11417-301

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia (NCT06073821)

Currently recruiting

BGB-11417-303

BGB-11417-303 A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT06943872)

Currently recruiting

BGB-11417-304

A Phase 3, Open-Label, Randomized Study of Sonrotoclax [BGB-11417] plus Zanubrutinib [BGB-3111] Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia (NCT07277231)

In patients with previously untreated chronic lymphocytic leukemia (CLL). The duration of each cycle is 28 days. Arm A: sonrotoclax + zanubrutinib up to 15 cycles. Arm B: venetoclax plus acalabrutinib up to 14 cycles.
Currently recruiting

BGB-16673 104

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies(NCT06634589)

Currently recruiting

BGB-16673-101

A Phase 1, Open-Label, Dose Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein Degrader BGB-16673 in Patients with B Cell Malignancies (BGB-16673-101) (NCT05006716)

Currently recruiting

BGB-16673-302

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors (NCT06846671)

Currently recruiting

BGB-16673-304

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT06973187)

The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).
Currently recruiting

BGB-3111-308

A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (NCT05100862)

Currently recruiting

BGB-3111-LTE1

An Open-label, Multi-centre, Long-term Extension Study of Zanubrutinib (BGB-3111) in patients with B-cell Malignancies (BGB-3111-LTE1) (NCT04170283)

No longer recruiting

BGB-A317-B167-101

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors (NCT05494762)

No longer recruiting

BGB-A317-LBL-007-201

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer (NCT05609370)

Currently recruiting

BGB-C354-001

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors (NCT06422520)

No longer recruiting

BHV3000-406

BHV3000-406: A Phase 4, Randomized, Doubleblind Placebo-Controlled, Efficacy and TolerabilityTrial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use (NCT05509400)

No longer recruiting

BHV7000-303

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy (NCT06309966)

This is a phase 2/3, global, multicenter, randomised, double-blind, placebo-controlled, 3-arm study designed to assess the efficacy and safety of BHV-7000 in participants with refractory focal onset epilepsy who are stable with atleast 1 and upto 3 antiseizure medications. The goals of this study are to: . See how well BHV-7000 works to decrease the number of seizures the participant has in a month as compared to a placebo (tablet with no medication). . See if BHV-7000 is safe and tolerable.
Coming soon
4 5 6 7 8